Monitor upcoming capital raises and reverse stock splits as indicators of financial distress. The shareholder rights agreement may deter potential acquirers, potentially limiting exit opportunities. Watch for continued Nasdaq compliance issues that could lead to delisting.
Executive Summary
SMX (Security Matters) Public Ltd Co is a foreign private issuer conducting an F-1/A filing to register up to 30,411,426 ordinary shares for resale by a selling stockholder under a Standby Equity Purchase Agreement (SEPA). The company has raised significant capital through convertible notes and equity lines but faces substantial doubt about its ability to continue as a going concern due to ongoing losses, significant liabilities, and reliance on continuous financing. Recent developments include a shareholder rights agreement (poison pill) and multiple reverse stock splits to maintain Nasdaq listing.
Key Facts
- Company faces substantial doubt about its ability to continue as a going concern (repeatedly stated in filing)
- Has incurred significant losses: $35.4M net loss in 2024, $24.6M net loss in first half of 2025
- Relies on continuous financing through equity lines and convertible notes to fund operations
- Implemented a shareholder rights agreement (poison pill) that could deter acquisitions
- Conducted multiple reverse stock splits (75:1, 28.5:1, 4.1:1, 7:1, 10.89958:1, 8:1, 4.8828125:1) to maintain Nasdaq listing
- Has $14.45M in accounts payable and accrued liabilities as of June 30, 2025
- Received deficiency notices from Nasdaq for minimum bid price and failure to hold annual meeting
Financial Impact
Significant ongoing losses with no revenue growth, requiring continuous capital raises
Risk Factors
- Substantial doubt about going concern status
- Heavy reliance on continuous financing
- Significant dilution from equity raises
- Nasdaq listing compliance risks
- Potential for further reverse stock splits
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001493152-26-008355 |
| Exhibit: ex10-71.htm | 0001493152-26-008355 |
| Exhibit: ex5-1.htm | 0001493152-26-008355 |
| Exhibit: ex10-73.htm | 0001493152-26-008355 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 11w ago | EFFECT | $16.95 | awaiting T+60 | — | $1.68 (+90.09%) |
Jul 28, 2026 12w ago | 6-K | $15.04 $1.83 | ▲ +87.83% | ▲ +92.56% | $1.68 (+88.83%) |
Jul 17, 2026 14w ago | 6-K | $17.66 $3.79 | ▲ +78.54% | ▲ +83.38% | $1.68 (+90.49%) |
Jul 13, 2026 15w ago | EFFECT | $16.21 $3.79 | ▲ +76.62% | ▲ +80.61% | $1.68 (+89.64%) |
Mar 9, 2026 33w ago | EFFECT | $66.91 $18.94 | ▼ −71.69% | ▼ −83.68% | $1.68 (−97.49%) |
Feb 27, 2026 34w ago | F-1/A | $34.94 $8.85 | ▲ +74.67% | ▲ +84.00% | $1.68 (+95.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers